Introduction
The Pseudomonas genus is a complex of nonfermentative aerobic gram-negative bacteria commonly found in soil, water, and plants and often found in small numbers in the natural intestinal flora and skin of humans; it is considered the main pathogen in this group. Pseudomonas pathogens rarely cause disease and are categorized based on RNA/DNA similarity and conventional planting characteristics. Pseudomonas aeruginosa is widely distributed in nature and is often found in wet hospital environments. These bacteria can be colonized in healthy humans, acting as a saprophyte. 1 Several species of this genus cause diseases in animals and plants. Most Pseudomonas microorganisms do not infect humans, but some of them are potentially important pathogens for hosts with impaired immune systems. Usually human infections are severe and difficult to treat because of resistance to different conventional antibiotics and weak host conditions. Pseudomonas aeruginosa is the most common human pathogen in the pseudomonas genus. Pseudomonas aeruginosa is the third most common cause of nosocomial infections after Staphylococcus aureus and Escherichia coli in some hospitals. These bacteria is a major pathogen and the leading cause of mortality in patients with cystic fibrosis, neoplasms, and severe burns.
2 In recent years, drug resistance has significantly increased in different pathogenic bacteria and has made the treatment of infections difficult. Therefore, there is a growing need for safe and effective drugs for use in treating drug-resistant infections.
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Pseudomonas aeruginosa is naturally resistant to several antibiotics and can be resistant to antibiotics such as penicillin, ceftazidime, ciprofloxacin, aminoglycosides, and carbapenems. The prevalence of antibiotic resistance is increasing; more than 10% of strains isolated across the world are resistant to multiple drugs. 
An Introduction to Drug Resistance
Resistance to antimicrobial agents and antibiotics among human pathogens has now entered the phase of multiple drug resistance (MDR). Despite the presence of numerous antibiotics and pharmaceutical factories and billions of dollars spent, the elimination of bacterial diseases is still far from mind, mainly due to the presence of numerous bacteria that resist the antibiotic effects. It is worth noting that for antibiotics to function better, how these substances act in the body should be considered. First, antibiotics should identify their target. Next, they must reach their proper concentration after reaching the target, and then they must maintain that concentration for a sufficient period of time. Some treatment problems are caused by the antibiotic's inability to selectively reach the target, cross the blood brain barrier, or reach the bacteria present in an abscess. The concentration of the antibiotic is also important. In some cases, it has been observed that antibiotics are rapidly excreted from or metabolized in the body, and this reduces the serum concentration of antibiotic, resulting in the ineffective treatment of bacterial infections that require large amounts of drug and prolonged contact with antimicrobial agents for elimination. In some cases, however, the antibiotic concentration may increase rapidly in a particular organ or specific tissue, while infectious parts may remain out of its reach. The mechanism of antibiotic resistance can be genetic or non-genetic. Today, in addition to trying to produce semi-synthetic antibiotics from existing antibiotics to be effective against resistant strains, attempts have been made to extend the recommendations for the proper use of antibiotics as much as possible in order to prevent the emergence of resistant strains.
5

Multidrug Resistance
Many bacteria are resistant to several classes of antibiotics (at least three different classes) and use various strategies to overcome the stress induced by an antibiotic's chemotherapeutic effect. These bacteria are called MDR, which are a major concern today in hospitals and other medical centers. MDR strains of Pseudomonas aeruginosa have been shown to exist in hospitals, isolated from the environment and hands of the personnel. Studies in Iran have shown that the multiple drug resistance of Pseudomonas aeruginosa strains has reached a worrying level in nosocomial infections. 6 The main mechanism of resistance in these bacteria is the active transfer of drugs from the cell to the environment through pumps that send out a wide range of compounds harmful to bacteria, such as antibiotics. Additionally, the mutation of antibiotic target sites or the synthesis of enzymes changing the drug can induce MDR resistance in bacteria. In all of these cases, bacterial strains carrying resistive factors are selected through the use of antimicrobial molecules, because sensitive strains are eliminated, while resistant strains grow and survive. 
Treatment of Infections Caused by Pseudomonas aeruginosa Bacteria
One of the most important causes of nosocomial infections is the definite spread of drug resistance.
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Resistance to antimicrobial agents among numerous pathogens, especially pathogens affecting nosocomial infections that impair the treatment of infections, has extended globally, leading to increased mortality rates in patients in different hospital wards.
9 Pseudomonas aeruginosa is the most common human pathogen of the pseudomonas genus and the third most common cause of nosocomial infections after Staphylococcus aureus and Escherichia coli, which leads to mortality in patients suffering from cystic fibrosis, neoplasms, and severe burns. 5 The term "nosocomial infection" refers to a serious disease unrelated to the underlying disease of the person seeking treatment in a hospital. 6 Treatment for pseudomonas infection is difficult, and treatment with appropriate drugs is not always successful. Pseudomonas aeruginosa infections should not be treated with one drug, as resistant strains develop quickly. Penicillins effective against these bacteria include ticarcinin, mesocillin and piperacillin, usually prescribed with an aminoglycoside such as gentamicin, tobramycin or amikacin. Other drugs effective against pseudomonas aeruginosa include aztreonam, imipenem, new quinolones including ciprofloxacin, and new generation cephalosporins such as cefaprazone. Ceftazidime is also used in the initial treatment of pseudomonas aeruginosa infections.
5
Discussion
Antibiotic resistance to gram-negative bacilli, especially enterobacteriaceae, pseudomonas aeruginosa, and acinetobacter, has become a growing problem around the world. Resistant bacteria can significantly impede the treatment maintenance.
9 Several studies have addressed antibiotic resistance in different countries, most of which suggest using microbial and molecular techniques together as reliable and documented tools. Antibiotic resistance in aztreonam was 1% in France, 48.8% in Russia, 11.9% in the United States (USA), 23% in Spain, and 66.7% in Isfahan, Iran.
7, 10-13 Antibiotic resistance to tobramycin has been reported as 25% in France, 5.4% in the USA, 10% in Spain, and 91.7% in Isfahan, Iran, which is alarmingly high; in other words, it is possible that in the near future, no other antibiotic will be effective against pseudomonas infections in Isfahan. 7, 10, 12, 13 The antibiotic resistance to ticarcillin was 38% in France and 64% in Canada. According to the results of the present study, the resistance to this antibiotic was 83.3% in Isfahan, which is significantly higher than the abovementioned regions and indicates the low effect of this antibiotic in Isfahan, possibly due to the wide use of this antibiotic in treatment regimens. 13, 14 The antibiotic resistance to ceftazidime was reported as 9% in France, 12.3% in Brazil, 26% in Turkey, 4.6% in Japan, 35% in Russia, 12% in Canada, 11.1% in the USA, 15% in Spain, and 75% in Isfahan. 7, 10, 11, 15, 16 Resistance to imipenem was 18.5% in France and 3.8% in Japan.
12, 16
Conclusion
According to the results of studies, it can be concluded that antibiotic resistance is higher in developing countries than developed countries, possibly due to the International Journal of Medical Reviews. 2017;4(2):40-42 excessive use of antibiotics in developing countries or the control of antibiotic use in developed countries.
